FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Galettis

Research Profile

Chemicals & Drugs

Disorders

Neoplasms

Living Beings

Procedures

Concepts & Ideas

Anatomy

HCT116 Cells

Co-author Network

Publications

TOP 3
Anahid Ehteda; Peter Galettis; Krishna Pillai; David L Morris
Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice.
Anahid Ehteda; Peter Galettis; Stephanie Wai Ling Chu; Krishna Pillai; David L Morris
Complexation of albendazole with hydroxypropyl-β-cyclodextrin significantly improves its pharmacokinetic profile, cell cytotoxicity and antitumor efficacy in nude mice.
Susan Manners; Peter Galettis; Paul de Souza
Conditions causing gemcitabine crystallization.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Galettis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Anahid Ehteda; Peter Galettis; Krishna Pillai; David L Morris
Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice.
BMC cancer 2013;13():86.
2012: Anahid Ehteda; Peter Galettis; Stephanie Wai Ling Chu; Krishna Pillai; David L Morris
Complexation of albendazole with hydroxypropyl-β-cyclodextrin significantly improves its pharmacokinetic profile, cell cytotoxicity and antitumor efficacy in nude mice.
Anticancer research 2012;32(9):3659-66.
2011: Susan Manners; Peter Galettis; Paul de Souza
Conditions causing gemcitabine crystallization.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2011;17(4):395-9.
2011: Ekkaphon Metharom; Peter Galettis; Susan Manners; Maria Jelinek; Winston Liauw; Paul L de Souza; Janelle M Hoskins; Matthew Links
The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
Asia-Pacific journal of clinical oncology 2011;7(1):65-74.
2010: Ekkaphon Metharom; Peter Galettis; Susan Manners; Matthew Links
Modulation of gemcitabine accumulation by DNA-damaging agents: mechanisms and specificity in an in vitro model.
Anticancer research 2010;30(9):3669-73.
2010: Kieran Scott; Mila Sajinovic; Juliane Hein; Sheri Nixdorf; Peter Galettis; Winston Liauw; Paul L de Souza; Qihan Dong; Garry G Graham; Pamela J Russell
Emerging roles for phospholipase A2 enzymes in cancer.
Biochimie 2010;92(6):601-10.
2010: Mohammad H Pourgholami; Zhao Y Cai; Stephanie W L Chu; Peter Galettis; David L Morris
The influence of ovarian cancer induced peritoneal carcinomatosis on the pharmacokinetics of albendazole in nude mice.
Anticancer research 2010;30(2):423-8.
2010: Mohammad H Pourgholami; Michael Szwajcer; Melvin Chin; Winston Liauw; Jonathan Seef; Peter Galettis; David L Morris; Matthew Links
Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2010;65(3):597-605.
2008: Xuemin Jiang; Peter Galettis; Matthew Links; Paul L Mitchell; Andrew J McLachlan
Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate.
British journal of clinical pharmacology 2008;65(3):326-33.
2008: Johnson J Liu; Peter Galettis; Alistair Farr; Lenushka Maharaj; Hasitha Samarasinha; Adam C McGechan; Bruce C Baguley; Richard J Bowen; Susan J Berners-Price; Mark J McKeage
In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.
Journal of inorganic biochemistry 2008;102(2):303-10.
2007: Peter Grimison; Peter Galettis; Susan Manners; Maria Jelinek; Ekkaphon Metharom; Paul L de Souza; Winston Liauw; Matthew Links
Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(36):5704-9.
2007: Zhao-Yan Cai; Peter Galettis; Ying Lu; David L Morris; Mohammad H Pourgholami
Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration.
Anticancer research 2007;27(1A):417-22.
2006: Hui K Gan; Paul L Mitchell; Peter Galettis; Ian D Davis; Jonathan Cebon; Paul L de Souza; Matthew Links
A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.
Cancer chemotherapy and pharmacology 2006;58(2):157-64.
2000: D Screnci; Mark J McKeage; Peter Galettis; Trevor W Hambley; Brian Palmer; Bruce C Baguley
Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.
British journal of cancer 2000;82(4):966-72.
2000: Mark J McKeage; S J Berners-Price; Peter Galettis; R J Bowen; W Brouwer; L Ding; L Zhuang; Bruce C Baguley
Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes.
Cancer chemotherapy and pharmacology 2000;46(5):343-50.
1999: Mark J McKeage; G G Haddad; L Ding; Peter Galettis; D Screnci; L Zhuang; Bruce C Baguley
Neuroprotective interactions in rats between paclitaxel and cisplatin.
Oncology research 1999;11(6):287-93.
1999: Matthew Links; S Watson; K Lethlean; W Aherne; F Kirsten; S Clarke; M Law; M Friedlander; Peter Galettis; Mark J McKeage
Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin.
Cancer investigation 1999;17(7):479-85.
1997: D Screnci; H M Er; Trevor W Hambley; Peter Galettis; W Brouwer; Mark J McKeage
Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.
British journal of cancer 1997;76(4):502-10.